Promethera Biosciences opens the French part of its phase I/II clinical trial in cell therapy

Promethera successfully administers Promethera® HepaStem in an adolescent suffering from an Urea Cycle Disorder at Hôpital Jeanne de Flandre (Lille, France)

Mont-Saint-Guibert (Belgium) - February 27, 2013 – Promethera Biosciences, a Belgian biotechnology company developing Promethera®HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial. The intervention was performed in January 2013 at the University Children’s Hospital Jeanne de Flandre in Lille (France). 

Sign Up